Skip to main content

Treatment Clinical Trials for Bladder Cancer

Review the bladder cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 113

Atezolizumab with Cisplatin or Carboplatin and Etoposide Followed by Cystectomy for the Treatment of Patients with Localized Small Cell Neuroendocrine Bladder Cancer
Status: Active
Location: 2 locations
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Status: Active
Location: 3 locations
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Status: Active
Location: 3 locations
Durvalumab Plus Monalizumab for the Treatment of Non-muscle Invasive Bladder Cancer in Patients Unresponsive to Bacillus Calmette-Guerin or with Exposed Cancer in Situ, ENHANCE Trial
Status: Active
Location: 2 locations
Enfortumab Vedotin plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Status: Active
Location: 3 locations
At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls
Status: Active
Location: 2 locations
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Status: Active
Location: 2 locations
Study of DF1001 in Patients with Advanced Solid Tumors
Status: Active
Location: 3 locations
A Beta-only IL-2 ImmunoTherapY Study
Status: Active
Location: 2 locations
Implantable Microdevice for Evaluation of Drug Response in Patients with Localized Bladder Cancer Undergoing Radical Cystectomy
Status: Active
Location: 2 locations
Comparing the Impact of Prostate Capsule-Sparing Cystectomy Compared to Nerve-Sparing Radical Cystectomy on Functional Outcomes in Patients with Bladder Cancer
Status: Active
Location: 2 locations
An Additional Bladder Biopsy before Surgery in Diagnosing Patients with Non-muscle Invasive Bladder Cancer
Status: Active
Location: 2 locations
Image Guided Radiation Therapy with MRI for the Treatment of Cancer, CONFIRM Study
Status: Active
Location: 2 locations
Hypotonic Fluids versus Chemotherapy Wash for the Prevention of Bladder Cancer in Patients with Upper Tract Urothelial Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
A Study Comparing Standard Treatments in People With Non-muscle Invasive Bladder Cancer (NMIBC), COMPARE IT Trial
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Local Consolidative Therapy to Extend the Efficacy of Systemic Therapy in Oligoprogressive Metastatic Cancer, EXTEND-OP Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Sacituzumab Govitecan before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Partial Cystectomy and Extended Pelvic Lymph Node Dissection with Standard of Care Systemic Therapy for the Treatment of Muscle-Invasive Bladder Cancer
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients with Metastatic Urothelial Bladder Cancer and other Solid Tumors
Status: Active
Location: Northwestern University, Chicago, Illinois
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Therapeutic Plasma Exchange with Enfortumab Vedotin and Pembrolizumab for the Treatment of Metastatic Refractory Bladder and Urinary Tract Cancers, RECIPE-B1 Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Adjuvant Sacituzumab Govitecan and Nivolumab for the Treatment of Patients with Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California